14 analysts have shared their evaluations of Biogen (NASDAQ:BIIB) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares ...

Biogen recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, despite these ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen has arrived at a highly unusual solution to a dispute surrounding a patent for its blockbuster multiple sclerosis drug Tecfidera. It has agreed to pay Denmark’s Forward Pharma $1.25 ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline, despite the market's current undervaluation. Sage's Zuranolone shows strong market ...

Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new building in Kendall Square in 2028, consolidating its various branches and ...